Boston Scientific Corporation(BSX)- NYSE
  • Fri, Sep. 2, 8:06 AM
    • Boston Scientific (NYSE:BSX) upgraded to Buy from Hold with a $33 (36% upside) price target by Argus Research.
    • Novo Nordisk (NYSE:NVO) upgraded to Hold from Reduce by HSBC.
    • Karyopharm (NASDAQ:KPTI) upgraded to Buy from Hold by Jefferies. Price target raised to $12 (8% upside) from $9.
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold with a $38 (17% upside) price target by Argus Research.
    • Quest Diagnostics (NYSE:DGX) downgraded to Neutral from Buy with an $86 (4% upside) price target by Mizuho Securities.
    | Fri, Sep. 2, 8:06 AM | 2 Comments
  • Thu, Jul. 28, 8:13 AM
    • Boston Scientific (NYSE:BSX) Q2 results ($M): Total Revenues: 2,126 (+15.4%); Cardiovascular: 837 (+12.7%); Rhythm Management: 537 (+3.9%); MedSurg: 752 (+29.0%).
    • Interventional Cardiology: 579 (+12.4%); CRM: 477 (+3.7%); Endoscopy: 361 (+10.7%); Defibrillator Systems: 333 (+52.8%); Peripheral Interventions: 258 (+13.2%); Urology & Pelvic Health: 256 (+89.6%); Pacemaker Systems: 144 (+136.1%); Neuromodulation: 135 (+10.7%).
    • Net Income: (207) (-302.9%); Non-GAAP Net Income: 435 (+28.3%); EPS: (0.15) (-287.5%); Non-GAAP EPS: 0.27 (+22.7%).
    • 2016 Guidance: Revenues: $8.27B - 8.37B from $8.075B - 8.225B; EPS: $$0.30 - 0.35 from $0.64 - 0.69; Non-GAAP EPS: $1.07 - 1.11 from $1.06 - 1.10.
    • Q3 Guidance: Revenues: $2.035B - 2.085B; EPS: $0.13 - 0.15; Non-GAAP EPS: $0.25 - 0.27.
    • Shares are up 4% premarket on increased volume.
    | Thu, Jul. 28, 8:13 AM | 1 Comment
  • Thu, Jul. 28, 6:31 AM
    • Boston Scientific (NYSE:BSX): Q2 EPS of $0.27 in-line.
    • Revenue of $2.13B (+15.8% Y/Y) beats by $80M.
    • Press Release
    | Thu, Jul. 28, 6:31 AM
  • Wed, Jul. 27, 5:30 PM
  • Wed, Jul. 27, 9:46 AM
    • Boston Scientific (BSX -1.1%) acquires privately held Cosman Medical for an undisclosed sum. The Burlington, MA-based firm commercializes radiofrequency ablation (RFA) systems to treat chronic pain.
    • BSX will fold Cosman into its Neuromodulation business. The impact of the transaction to non-GAAP EPS will be neutral this year and accretive thereafter.
    | Wed, Jul. 27, 9:46 AM
  • Wed, Jul. 20, 7:24 AM
    • Boston Scientific (NYSE:BSX) is poised to ink a settlement agreement with the IRS related to a disputed tax liability related to transfer pricing issues for Guidant for the years 2001 - 2006 and BSX's tax years 2006 and 2007. If the settlement is finalized, BSX will pay $275M plus accrued interest.
    • The IRS asserted that the company owed $1.162B plus interest related to transfer pricing between domestic and foreign subsidiaries of Guidant. The IRS also proposed adjustments related to the financial terms of BSX's deal with Abbott Laboratories (NYSE:ABT) pertaining to the sale of Guidant's vascular intervention business to Abbott in April 2006 (details are on page 99 of BSX's 2015 10-K).
    • Boston Scientific acquired Guidant for $27B in early 2006.
    | Wed, Jul. 20, 7:24 AM
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM
  • Thu, Jun. 9, 6:51 AM
    • With the aim of building on its progress in executing its long-term growth strategies, Boston Scientific (NYSE:BSX) announces a global restructuring program that should reduce annual pre-tax operating expenses by $115M - $150M by 2020. The company intends to reinvest the savings into its growth initiatives.
    • Pre-tax charges will be $175M - 225M. The overall number of employees should remain relatively unchanged although some attrition is expected. All activities should be completed or close to completion by the end of 2018.
    • Specific actions are not disclosed.
    | Thu, Jun. 9, 6:51 AM | 1 Comment
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Thu, May 19, 10:26 AM
    • The FDA approves Boston Scientific's (BSX -0.5%) Precision Montage MRI Spinal Cord Stimulator System for the relief of chronic pain. The company plans to introduce the device at the 8th World Congress of the World Institute of Pain in New York, May 20-23.
    • The product enables patients to undergo a full-body MRI while still benefiting from the pain relief of Precision Montage's MultiWave Technology, based on its proprietary Illumina 3D neural targeting algorithm, a computer model designed to assist doctors with point-and-click targeting in treating pain.
    | Thu, May 19, 10:26 AM
  • Wed, Apr. 27, 9:11 AM
    | Wed, Apr. 27, 9:11 AM | 1 Comment
  • Wed, Apr. 27, 7:01 AM
    • Boston Scientific (NYSE:BSX) Q1 results ($M): Total Revenues: 1,964 (+11.1%); Cardiovascular: 790 (+11.0%); Rhythm Management: 492 (-4.3%); MedSurg: 682 (+25.8%).
    • Key Segments: Interventional Cardiology: 548 (+10.7%); CRM: 433 (-5.0%); Endoscopy: 333 (+9.2%); Defibrillator Systems: 311 (-7.2%); Peripheral Interventions: 242 (+11.5%).
    • Net Income: 202 (+999%); Non-GAAP Net Income: 378 (+32.2%); EPS: 0.15 (+999%); Non-GAAP EPS: 0.43 (+104.8%).
    • 2016 Guidance: Revenues: $8.075B - 8.225B from $7.900B - 8.100B; EPS: $0.64 - 0.69 from $0.62 - 0.67; Non-GAAP EPS: $1.06 - 1.10 from $1.03 - 1.07.
    • Q2 Guidance: Revenues: $1.927B - 1.980B; EPS: $0.14 - 0.17; Non-GAAP EPS: $0.25 - 0.27.
    | Wed, Apr. 27, 7:01 AM
  • Wed, Apr. 27, 6:31 AM
    • Boston Scientific (NYSE:BSX): Q1 EPS of $0.28 beats by $0.04.
    • Revenue of $1.96B (+10.7% Y/Y) beats by $50M.
    • Press Release
    | Wed, Apr. 27, 6:31 AM
  • Tue, Apr. 26, 5:30 PM
    | Tue, Apr. 26, 5:30 PM | 9 Comments
  • Mon, Apr. 25, 4:57 PM
    • Boston Scientific (NYSE:BSX) announces that its has received FDA approval for its ImageReady MR-Conditional Pacing System safe for use in a magnetic imaging (MRI) environment. The approval covers the ACCOLADE MRI and ESSENTIO MRI pacers and the new INGEVITY MRI pacing leads.
    | Mon, Apr. 25, 4:57 PM
  • Wed, Mar. 23, 1:13 PM
    • The FDA has approved privately held Stimwave, LLC's StimQ Peripheral Nerve Stimulator (PNS) System for the relief of severe intractable chronic pain of peripheral origin. StimQ PNS is a wireless, fully programmable PNS neuromodulation device that can be implanted through a standard needle-size insert or small incision. According to the company, the product's small size minimizes the need for surgery and is much more patient-friendly, avoiding the larger cables and bulky components of other neuromodulators.
    • StimQ is less than 5% of the size of other implanted pain relief devices. it is powered by a small fabric patch unit that is worn on the body.
    • Pain relief device-related tickers: (STJ -0.1%)(BSX -1%)(MDT -0.2%)(GB +2.9%)(NURO -1.6%)
    | Wed, Mar. 23, 1:13 PM